Founded in Aug. 2017, NeoCura Bio-Medical Technology Co., Ltd. (¡°NeoCura¡± for short) is committed to building a global leading RNA innovative drug platform. It has built multi-omics big data collection platform and multi-biomics database to perform in-depth drug target mining and fully automated drug design based on AI algorithm and core bioinformatic technologies. Through application in clinical innovative RNA drug development and next-generation, safe, and efficient clinical precision diagnosis and treatment, NeoCura provides patients with one-stop full-cycle solution from screening, diagnosis, treatment to efficacy monitoring.
Technical Superiority
Team
Advantage
AI algorithm + real-world data validation facilitates clinical research of RNA drugs and fully automated drug design based on AI algorithm and core bioinformatic technologies£»
NeoCura has applied for more than 30 patents of inventions in China and more than 10 patents of inventions abroad based on its core technologies;
Hundreds of articles published in Nature, Science, Cell, Nature Methods, Immunity, and other global top journals;
Research Strengths
Academic Achievements
ABOUT US
The R&D team consists of dozens
of doctors/post-doctors from prestigious schools such as Harvard University, Cornell University, Tsinghua University, Peking University, and Chinese Academy of Sciences;
|
|
